Abstract:Introduction: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer, with limited targeted treatment options. TNBC patients can, however, benefit from targeted drugs known as Poly (ADP-Ribose) Polymerase inhibitors (PARPi). PARPi disrupt DNA repair pathways by targeting tumors with germline BRCA1/2 mutations (BRCA-MUT) via synthetic lethality and PARP-DNA trapping mechanisms. Only 15-20% of the TNBC patient population are BRCA-MUT and can thus benefit from PARPi. However, preclinical studies and clinical trials have suggested that PARPi can also be effective in BRCA1/2 wild-type (BRCA-WT) cancer cells that have genomic phenotypes similar to BRCA-MUT cells, a phenomenon known as BRCAness. Previously, we used whole transcriptome analysis in a panel of TNBC cell lines to identify a 63-gene signature for BRCAness. The 63-gene signature was shown to predict response to PARPi with an accuracy of 86% in patient-derived xenografts, and was present in 45% of TNBC patients. We hypothesize that targeting genes in this 63-gene signature can enhance the sensitivity of PARPi in BRCA-WT and BRCA-MUT TNBC cells. Our aim is to identify and target genes from this signature that are involved in DNA synthesis and repair pathways, to identify effective combination strategies with PARPi. Methods: Using a PARPi-resistant TNBC cell line, MDAMB231, we carried out an siRNA screen of six genes from the 63-gene signature (BARD1, BUB1, RRM2, FEN1, EXO1, and USP1), chosen based on DNA repair functions and small-molecule inhibitor availability. The gene knockdowns were combined with the application of a potent PARPi, talazoparib, to determine the impact on DNA damage and cell death in TNBC cell lines. We then focused on targeting FEN1 function with the inhibitor LNT1. Using the Chou & Talalay combination index, we combined LNT1 with talazoparib to determine drug synergy in TNBC cell lines. Results: The individual siRNA knockdowns of BARD1, BUB1, FEN1, EXO1, and USP1, in combination with talazoparib, led to increased γ-H2AX and cleaved-caspase 3 levels, indicating augmentation of DNA damage and apoptosis. In particular, the FEN1 inhibitor, LNT1 demonstrated efficacy as a single-agent and synergy in combination with talazoparib in both BRCA-WT and BRCA-MUT TNBC cell lines. Conclusions: The siRNA screens, in combination with talazoparib, show that there are indeed targets within the 63-gene signature that can be used with PARPi that enhance DNA damage and cell death. The drug synergy shown between LNT1 and talazoparib in both BRCA-WT and BRCA-MUT TNBC cells suggests that LNT1 with PARPi could be an effective targeted combination approach, with great potential for TNBC patients. Citation Format: Elicia Fyle, Djihane Abdesselam, Mallory Frederick, Saima N. Hassan. Characterization of PARP inhibitor combination therapies in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4529.

Synergistic Effect of Ubiquitin-Specific Protease 14 and Poly(ADP-Ribose) Glycohydrolase Co-Inhibition in BRCA1-Mutant, Poly(ADP-Ribose) Polymerase Inhibitor-Resistant Triple-Negative Breast Cancer Cells

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer

Increasing radiosensitivity by the combined inhibition of PARP1 and PI3K in BRCA1-mutated triple negative breast cancer

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Abstract 5941: Small molecule NSC59984 synergizes with PARP inhibitors in BRCA1 wild type ovarian cancer

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

CRISPR/Cas9‐mediated Mutagenesis to Validate the Synergy Between PARP1 Inhibition and Chemotherapy in BRCA1‐mutated Breast Cancer Cells

Abstract 4529: Characterization of PARP inhibitor combination therapies in triple-negative breast cancer

Differential Immunomodulatory Effect of PARP Inhibition in BRCA1 Deficient and Competent Tumor Cells

Abstract LB271: Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors

Combining 53BP1 with BRCA1 As a Biomarker to Predict the Sensitivity of Poly(adp-Ribose) Polymerase (PARP) Inhibitors

Glycogen Synthase Kinase 3β Inhibition Synergizes with PARP Inhibitors Through the Induction of Homologous Recombination Deficiency in Colorectal Cancer.

Abstract 7595: PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells

Abstract 4527: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stress

Abstract B032: USP1 inhibition induces single strand DNA gap accumulation and overcomes PARP inhibitor resistance in BRCA1 deficient cancer cells

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells

Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA -proficient cancer cells to PARP inhibitors

Abstract 7146: HSK39775: A USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies